NASDAQ$ZBIO
Zenas Biopharma Inc · Q3 2024 earnings
Q3 2024 earnings ·
Briefing
ZBIO Q3 2024 — $149.5M revenue
The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could diff. Zenas Biopharma Inc reported Q3 2024 results. Net income of $104.4M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $149.5M.
- Net income: $104.4M.
- Filed on Form 10-Q (accession 0001558370-24-015162).
Headline financials
Revenue & EPS history
Zenas Biopharma Inc · Revenue · Quarterly
$50M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 4 quarterly earnings reports · overlaid with Q3 2024
+4.3%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+3.2%
Avg return
30 days after
80%
4 / 5 earnings
Positive
+12.2%
Q1 2025
Best reaction
-3.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -11.7% | +3.0% | |
| Q3 2025 | +1.7% | +1.9% | +15.3% | |
| Q2 2025 | +6.7% | +12.8% | +35.3% | |
| Q1 2025 | +12.2% | +32.3% | +19.0% | |
| Q3 2024 | -3.1% | -19.6% | -56.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro